Aethlon Medical, Inc. (NASDAQ:AEMD) Offering Spooks Investors

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. (NASDAQ:AEMD) fell 37.7% after announcing the pricing of a public offering of 5.5 million units. Each unit comprises of one share of common stock and a warrant for the purchase of one share of common stock. The therapeutic technology company expects the offering to generate gross proceeds of $6 million.

AEMD Stock Performance

Aethlon Medical, Inc. (NASDAQ:AEMD)

The company intends to use net proceeds from the offering to finance clinical development of its product candidates as well as for working capital and other general corporate purposes. Investors reacted angrily to the public offering, sending the stock lower in the market.

Aethlon Medical, Inc. (NASDAQ:AEMD) has already broken a key support level after plunging to multi-year lows of $0.96 a share. The stock has underperformed the overall industry this year after losing more than 70% in market value.

Investors’ confidence in the stock has turned sour ever since Aethlon Medical, Inc. (NASDAQ:AEMD) reported a second-quarter net loss of (-$1.8) million. Operating expenses in the quarter came in at $1.16 million compared to $1.14 million reported last year. The company attributed the increase to an increase in payroll and other related expenses.

A move to raise more money through the public offering does not come as a surprise as the company exited the second quarter with cash and cash equivalent of $327,000.

Hemopurifier EPA Designation

Separately, The U.S. Food and Drug Administration (FDA) has granted the therapeutic technology company an Expedited Access Pathway for the development of Hemopurifier, for the treatment for life-threatening viruses.

The agency normally grants the designation to products that demonstrate the potential to address unmet medical needs, especially in life-threatening conditions. The designation is designed to reduce the time and cost needed for the regulatory approval of a device or drug

Hemopurifier is designed to capture a broad spectrum of viruses that are highly glycosylated including strains of influenza viruses, Mosquito-borne viruses, and hemorrhagic viruses.

“We are honored to have our Hemopurifier® designated to the Expedited Access Pathway and additionally are pleased that FDA has also allowed our proposed “indication for use,” which provides the possibility of treating a wide range of life-threatening viruses versus a single disease condition,” said Jim Joyce, Chairman and CEO of Aethlon Medical.

In addition, the National Cancer Institute has granted Aethlon Medical, Inc. (NASDAQ:AEMD) a contract award worth $229,250. Dubbed ‘Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes’ the contract calls for two subcontractors to work under the therapeutic technology company.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AEMD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Is Mirati Therapeutics, Inc. (NASDAQ:MRTX) Topping?

Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Traders are active in Mirati Therapeutics, Inc. (NASDAQ:MRTX) and are sending the shares up over 2.0% on heavy volume as of 10:30 AM EST. Last Friday MRTX stock essentially doubled after the biotech company released a statement announcing positive Phase 2 trial data on its two non-small cell lung cancer treatment trials using sitravatinib in combination with nivolumab (OPDIVO®).

The volatility of MRTX shares is showing up clearly in their option pricing as MRTX options are reportedly now being offered at some of the highest intrinsic values of any stock trading. Clearly the street believes that Mirati Therapeutics, Inc. (NASDAQ:MRTX) future may have a significant upside potential.

MRTX Share Action

MRTX shares gapped up to open today’s session but traders sold off the gains. Volume has been very heavy. The 30-day, daily average volume for MRTX is just over 1 million shares but only one hour into trading over 3.25 million shares have traded. If that pace continues throughout the session, MRTX shares will trade over 17 times their average volume.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) has not traded above the $10 level since mid-2016 so resistance and support at current levels ($11.20) are dynamic and subject to shifting tides. However it is hard to deny that the stock is in rare air as the Relative Strength Index (RSI) hovers above 85. Typically, traders believe that a stock with an RSI above 70 is reaching “overbought” territory.

Mirati Therapeutics, Inc. (NASDAQ:MRTX)
One month MRTX stock price chart

Analyst Reaction to MRTX

Prior to the release of positive Phase 2 trial data, analysts had assigned a consensus price target of $10.80 to MRTX shares. Of the seven firms that followed Mirati Therapeutics, Inc. (NASDAQ:MRTX), four gave the stock a rating of “Strong Buy” while three gave MRTX shares a “Hold” rating. The analysts believe that MRTX earning’s growth will be about four times the average for a company in the biotech sector. However, Mirati Therapeutics, Inc. (NASDAQ:MRTX) has yet to post a profit. As a matter of fact, last year was the largest per share loss shareholders experienced over the last three years.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MRTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Curis, Inc. (NASDAQ:CRIS) Slumps 8% After Public Offering Pricing

Curis, Inc. (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS) shares fell 8% after the biotechnology company announced the pricing of an underwritten public offering of 20 million shares of common stock. The company has also granted underwriters 30-day option to purchase an additional 3 million shares. The offering is set to close on September 18, 2017 subject to customary closing conditions.

Stock Performance

Curis, Inc. (NASDAQ:CRIS) stock has been under selling pressure since the start of the month. The stock is currently trading in a range after failing to close above the $2.25 mark on three attempts. It now faces immediate support at the $1.60 level, below which it could drop to this year’s lows of $1.47 a share.

Curis, Inc. (NASDAQ:CRIS)
One month CRIS stock price chart

The underwritten stock pricing appears to have spooked investors given that in addition to increasing the company’s debt, it will lead to further dilution of the stock.   Part of the proceeds from the offering are to be used to fund potential acquisition of new businesses as well as technologies and products that have the potential to expand the business.

Curis, Inc. (NASDAQ:CRIS) will also use the funds to finance ongoing development of CUDC-907, a small molecule inhibitor of histone deacetylase as well as CA-170, CA-327, and CA-4948 in collaboration with Aurigene Discovery Technologies.

Curis Pipeline

Aurigene Discovery Technologies has announced plans to carry out Phase 2 trial of CA-170, an oral small molecule designed to target the immune checkpoints PDL and Vista. The company has already carried out Phase 1 trials in the U.S, South Korea, and Spain.

The company did not report any dose limiting toxicities on the Phase 1 trial of CA-170 as it also demonstrated good oral bioavailability. Evidence of immune modulation was observed in patients’ blood and tumor biopsy samples.

According to Aurigene CEO, CSN Murthy, the results affirm CA-170 mechanism action as an oral checkpoint inhibitor. Together with Curis, Inc. (NASDAQ:CRIS), the company has already designed a phase 2 trial that will target selected populations of patients in major centers in India.

“Based on these initial clinical results, we are excited for the opportunity to expand testing of CA-170, possibly in earlier lines of treatment and in a greater number of immunotherapy treatment-naïve cancer patients,” commented Mr. Murthy.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CRIS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Aethlon Medical, Inc. (NASDAQ:AEMD)’s Device Gets Accelerated FDA Review

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. (NASDAQ:AEMD) shares rallied 35.13% after the U.S. Food and Drug Administration (FDA) granted the life sciences and technology company Expedited Access Pathway Designation. The designation is for Aethlon Medical’s Hemopurifier device.

Investors Reaction

Investors reacted to the news sending the stock to highs of $3.80 a share before it retreated to close the day at $2.70 a share. The rally helped reverse a strong downtrend that had pushed the stock to lows around $1.20 a share. It awaits to be seen if a close above the $2.00 mark will help support the recent uptrend.

Aethlon Medical, Inc. (NASDAQ:AEMD) has been trading between $1.50-$3.85 after shedding more than 30% in market value since the start of the year. The FDA designation continues to fuel investor’s sentiments on the stock on the fact it could accelerate the approval of the Hemopurifier.

Aethlon Medical, Inc. (NASDAQ:AEMD)
One month AEMD stock price chart

Hemopurifier is designed to reduce the spread of pathogens in the patient’s circulatory system. The device can be used to treat a wide range of life threatening viruses. Currently, the device is being used to capture a broad spectrum of viruses, most of which are highly glycosylated, including life threatening strains of influenza viruses.

“We are honored to have our Hemopurifier® designated to the Expedited Access Pathway and additionally are pleased that FDA has also allowed our proposed “indication for use,” which provides the possibility of treating a wide-range of life-threatening viruses versus a single disease condition,” said Jim Joyce, Chairman, and CEO of Aethlon Medical, Inc. (NASDAQ:AEMD).

Aethlon Medical Hemopurifier Uncertainty

However, the Hemopurifier continues to be plagued by uncertainty as the next course of action after the FDA designation remains unknown. Aethlon Medical, Inc. (NASDAQ:AEMD) is yet to ascertain how it will proceed with clinical studies to determine the safety and efficacy of the device in highly virulent and pandemic threats. Currently, there is no FDA approved device the treatment of highly deadly viruses.

Separately, Aethlon Medical, Inc. (NASDAQ:AEMD) reported a net loss of ($1.4) million for the first fiscal quarter ended June 30, 2017, compared to a net loss of $2.2 million in Q2 2017 and $1.5 million in Q4 2017. The life sciences company exited the quarter with cash and cash equivalent of $327, 000 down from $1.4 million as of Q4 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AEMD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Gulf Resources, Inc. (NASDAQ:GURE) Regulatory Scrutiny Rattles Investors

Gulf Resources, Inc. (NASDAQ:GURE)

Gulf Resources, Inc. (NASDAQ:GURE) felt the wrath of Wall Street after announcing the closure of its Bromine, crude salt and chemical Chinese factories for rectification and improvement. The stock came under immense selling pressure, dropping 17.9% to end Thursday’s trading session at $1.64 a share.

Gulf Resources, Inc. (NASDAQ:GURE)
One month GURE stock price chart

Stock Sell Off

The sell-off saw the stock drop from highs of $2.00 after having rallied by more than 20% last month. The stock is currently trading in a $1.60 – $2.00 trading range. A close below the trading range could see the stock end up around the 52-week low of $1.53 a share.

Gulf Resources, Inc. (NASDAQ:GURE) is a holding company that specializes in the manufacture and sale of bromine and crude salt used in oil and gas field exploration. A sell-off of the stock comes to growing concerns about the potential impact of increased government scrutiny on the company.

Regulatory Scrutiny

Early last month, Gulf Resources, Inc. (NASDAQ:GURE) warned that a move by the government to enforce stringent environmental rules could significantly hurt its operations and earnings. The company’s subsidiaries, Shouguang City Haoyuan Chemical Company Limited, and Shouguang Yuxin Chemical Industry Co., Limited have since received letters from Yangkou County, Shouguang City.

In the letter, the local authorities order the immediate shutdown of the company’s production facilities pending rectification and improvements in accordance with new safety and environmental protection. The order comes even on Gulf Resources reiterating that its facilities were fully compliant.

“These are very interesting business situation,” Mr. Liu Xiaoping, the CEO of Gulf Resources, Inc. (NASDAQ:GURE) stated. “With most of the factories in industries such as mining and chemicals closed, there will be many people unemployed. In addition, these basic industries provide products for downstream industries. If they cannot produce products, downstream industries will also have to close.

Shutdown Impact

Gulf Resources, Inc. (NASDAQ:GURE) is currently in discussion with the local authorities as it seeks to resolve the standoff. The company says it might have to purchase new equipment and utilize modern technology, with respect to its bromine production, if it is to meet the environmental requirements.

Investments in new equipment for better waste water treatment among other investments could cost the company between $15 and $30 million. However, it remains unclear the kind of impact the shutdown will have on earnings and capital expenses.

The Chief Executive Officer is confident that the Chinese government will move with speed to complete inspections and agree on the necessary remediation and upgrading.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GURE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Delcath Systems, Inc. (NASDAQ:DCTH) Turns To Reverse Stock Split

Delcath Systems, Inc. (NASDAQ:DCTH)

Delcath Systems, Inc. (NASDAQ:DCTH) poor run in the market continued after the Chief Executive Officer, Jennifer K. Simpson, issued a letter to stockholders. The stock continues to trade at all-time lows and the company has been hit with a delisting notice by the NASDAQ capital markets.

Stock Performance

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) continue to trade in a downtrend in a tight $0.10 – $0.11 trading range. The strength of the sell-off wave threatens to push the stock to its 52-week lows having dropped from highs of $3 a share in late 2016. In a bid to shore up the stock price, the company has proposed a reverse stock split that it hopes shareholders will approve at an upcoming AGM.

Delcath Systems, Inc. (NASDAQ:DCTH)
One month DCTH stock price chart

Reverse Stock Split Push

According to Simpson, approval of the proposed reverse stock-split will result in the extinguishment of a Note with a majority note holder. The transaction should also adjust the floor price of the remaining note with a minority note holder.

Delcath Systems, Inc. (NASDAQ:DCTH) is also banking on the reverse stock-split to solve the minimum bid requirement for the NASDAQ. Regaining compliance is crucial as listing in the exchange allows the company to gain access to a wide range of capital opportunities.

“Should the Company not obtain approval for a reverse stock split, it is likely that the Company will be delisted from NASDAQ. We believe remaining on the NASDAQ provides liquidity and other benefits to the Company and its investors,” Delcath Systems, Inc. (NASDAQ:DCTH) in a statement.

Delcath Systems, Inc. (NASDAQ:DCTH) has also reached an agreement with a majority Note holder of Convertible notes through which 90% of the outstanding debt is to be extinguished upon the approval of the reverse stock-split . The transaction should mitigate potential future dilution of the stock-split.

In addition to reducing the amounts of outstanding shares, the reverse stock-split should provide Delcath Systems, Inc. (NASDAQ:DCTH) with the flexibility to raise equity capital. The company hopes to raise money to fund its clinical development programs as well as finance its commercial efforts in Europe.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DCTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Windstream Holdings, Inc. (NASDAQ:WIN) Wins Contract

Windstream Holdings, Inc. (NASDAQ:WIN)

Shares of Windstream Holdings, Inc. (NASDAQ:WIN) rose nearly 3.0% in the last session after the company announced a contract win with a major building supplier with operations across the US and Canada.

The stock jumped 2.99% to settle at $2.07, pushing Windstream Holdings, Inc. (NASDAQ:WIN)’s market cap to $383.6 million. The stock traded between a low of $2.01 and a high of $2.09 on the day. Despite the gain, Windstream has dropped more than 71% since the beginning of the year and has declined more than 75% since a year ago.

Considering where Windstream Holdings, Inc. (NASDAQ:WIN) closed in the last session, the stock is trading close to its one-year low. Over the last year, Windstream has traded between a low of $1.87 and a high of $10.45.

Windstream Holdings, Inc. (NASDAQ:WIN)
One month WIN stock price chart

Windstream wins large SD-WAN contract

The news that moved the Windstream Holdings, Inc. (NASDAQ:WIN) stock in the last session was the announcement of a potentially large contract, which could unlock more business for the company.

Windstream Holdings, Inc. (NASDAQ:WIN) said that a major, but unidentified, building supplier has selected Windstream to provide SD-WAN and Unified Communications as a Service (UCaaS) solutions. It said the solutions would enable the customer to increase the connectivity and productivity for its 3,500 workers located across the U.S. and Canada.

For the SD-WAN solution, the client selected Windstream’s SD-WAN Concierge service. This package includes what Windstream labels a “personalized and proactive guidance” from a dedicated technical service manager.

According to Windstream Holdings, Inc. (NASDAQ:WIN), its SD-WAN solution offers customers better network agility, seamless scalability as well as optimized performance. Windstream also touts its SD-WAN Concierge service for its cost benefits.

$28.7 billion revenue opportunity in UCaaS market

The customer tried Windstream Holdings, Inc. (NASDAQ:WIN)’s SD-WAN solution in four of its locations before it committed to the contract. The customer will now roll out Windstream’s SD-WAN Concierge to all of its 210 locations.

Under the UCaaS package, Windstream Holdings, Inc. (NASDAQ:WIN) is providing the customer with an integrated communications service that supports voice, instant messaging, and video conferencing.

According to research firm MarketsandMarkets, UCaaS market will be worth $28.7 billion by 2021, up from $17.4 billion in 2016. This shows the significant revenue potential Windstream has in this industry.

Winning large customers is not only great for Windstream Holdings, Inc. (NASDAQ:WIN) because of the increased revenue streams, but the wins also help raise the company’s profile in advanced communications technology market. Windstream, for instance, can reference its large customers to help it win more business.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $WIN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Netlist, Inc. (NASDAQ:NLST) Tanks

Netlist, Inc. (NASDAQ:NLST)

Netlist, Inc. (NASDAQ:NLST) stock is down almost 30%, to $0.60, at the opening of the market on a volume figure that indicates trading at over 127 times the daily average. Traders are reacting to the company’s pricing of its public offering of 8.5 million shares of its common stock at a price of $0.60 per share. Netlist has also granted the underwriters a 30-day option to purchase an additional 1.275 million shares of its common stock at $0.60 per share if the need arises to cover any over-allotments. The offering is expected to close on or about August 22, 2017.

Netlist, Inc. (NASDAQ:NLST)
One month stock price chart for NLST

The total gross proceeds are expected to be approximately $5.1 million. After deducting expenses, the net proceeds are expected to be approximately $4.5 million (assuming no exercise of the underwriters’ over-allotment option). The net proceeds will be used by Netlist, Inc. (NASDAQ:NLST) for general corporate purposes, including working capital and other general and administrative purposes.

The current slide in the price of NLST began on August 10, after Netlist, Inc. (NASDAQ:NLST) released Q2 2017 financials. The company’s net loss for the second quarter ended July 1, 2017, was (-$3.8) million, or (-$0.06) loss per share, compared to a net loss for the same period in the prior year of (-$1.5) million, or (-$0.03) loss per share. The slide has continued through the announcement of the dilutive public offering as NLST shares have hit new 52-week lows, eclipsing the old low of $0.83.

Irvine, CA-based Netlist, Inc. (NASDAQ:NLST) is a global provider of high-performance modular memory subsystems to original equipment manufacturers. Netlist specializes in hybrid memory – the merging of DRAM and NAND flash raw materials to create memory solutions. The Company’s patented memory technologies claims to supply superior performance, and high density in a cost-efficient solution.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NLST and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Delcath Systems, Inc. (NASDAQ:DCTH) Rallies

Delcath Systems, Inc. (NASDAQ:DCTH)

Delcath Systems, Inc. (NASDAQ:DCTH) continues to edge higher as it builds on a momentum that began early in the month. The stock was up by 36.76% in Wednesday’s trading session as investors reacted to a stellar second quarter, where reported revenues were up 20% year-over-year.  The company has also announced plans to carry out a reverse stock split as it looks to raise funds through the issuance of stock to finance operations.

Delcath Systems, Inc. (NASDAQ:DCTH)
One month stock price chart for DCTH

Stock Performance

Momentum continues to build up around Delcath Systems, Inc. (NASDAQ:DCTH) awaiting to see if the stock will rally. Shares traded have almost doubled to highs of 122 million. However, the stock has underperformed the overall industry and is down from highs of $3 a share.

Reports that Medizinische Hochshule Hannover is using Delcath Systems, Inc. (NASDAQ:DCTH) chemosaturation for the treatment of liver cancer appears to be fuelling renewed investor interest in the stock. The German medical facility has reportedly used innovative minimally invasive treatment in 100 patients.

The life-saving cancer treatment is currently approved in Europe as Delcath Systems, Inc. (NASDAQ:DCTH) continues to work on multiple clinical trials in pursuit of approval in the U.S. Approval in the U.S would be a milestone achievement, which could push the stock even higher in the charts.

Europe Sales Push

A 20% increase in second quarter revenue to highs of $0.6 million underscored growing demand for the company’s products in key markets. Delcath Systems, Inc. (NASDAQ:DCTH) attributes the increase to the establishment of ZE diagnostic reimbursement for Chemosat in Germany. The company plans to leverage the Positive reimbursement support in pursuit of market access in other countries such as the U.K and the Netherlands.

“During the first half of 2017 we continued to advance our clinical development programs in ocular melanoma liver metastases (OM) and intrahepatic cholangiocarcinoma (ICC), while making steady progress with the ongoing commercialization of CHEMOSAT in Europe,” said Jennifer K. Simpson, Delcath Systems, Inc. (NASDAQ:DCTH) CEO.

Separately, Delcath Systems, Inc. (NASDAQ:DCTH) has confirmed plans to carry out a reverse stock split having reached the maximum amount of authorized shares of common stock. The company plans to use the split to access $11.8 million of cash currently in restricted accounts associated with convertible notes issued last year.   The split should also allow the company to regain compliance with the NASDAQ capital markets listing requirements.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DCTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OXIS International, Inc. (OTCMKTS:OXIS) Stock Explodes On Merger Talk And Pipeline Of Drugs

OXIS International, Inc. (OTCMKTS:OXIS)

OXIS International, Inc. (OTCMKTS:OXIS) stock was up by 60.98% in Monday’s trading session as investors await an upcoming conference where the company plans to discuss its oncology and central nervous system drugs. More than 300 companies will attend the conference scheduled for September 10 to September 12 at the Lotte New York Palace Hotel.

OXIS Stock Price Chart:

OXIS Stock
One month price chart for OXIS stock

Shares of OXIS International, Inc. (OTCMKTS:OXIS) are up by more than 100% since the end of July and currently trading at the higher end of $06 – $0.09 trading range. The stock’s impressive run, which began last month, faces a major test at the $0.10 a share mark, which is acting as a key resistance level. Above the $0.10 mark, the stock could rally to highs of $0.20 a share.

OXIS International, Inc. (OTCMKTS:OXIS) is an immuno-oncology company focused on the treatment of cancer and other unmet medical needs. Its candidate drug is 0XS-1550 designed to target cancer cells expressing the CD19 receptor or CD22 receptor.

Fuelling the bullish momentum on OXIS International, Inc. (OTCMKTS:OXIS) stock is the pending merger with GT BioPharma and Georgetown Translational Pharmaceutical. The merger will result in a combined company that combines Oxis promising oncology drugs as well as GT BioPharma central nervous systems drugs. The deal should close before September 30, 2017.

“The merger of GT BioPharma, Inc. (Oxis) and GTP will greatly accelerate the clinical development of exciting new treatments to meet the medical needs of those suffering from cancer and neurologic diseases,” said CEO Dr. Clarence-Smith.

OXS-1550 Development

OXIS International, Inc. (OTCMKTS:OXIS) in partnership with Europe Paris Oxis has confirmed the enrollment of four patients as part of a Foods and Drug Administration approved Phase 2 Clinical trial of 0XS-1550. The trial is currently being conducted by the University of Minnesota’s Masonic Cancer Center.

Researchers at the university have already completed a Phase 1 trial of the promising cancer therapy where they ascertained safety and effective dosage. Phase 2 trial results are slated for release sometime in the first quarter of 2018.

“The product performed well in Phase 1 studies of blood cancers and we look forward to providing a targeted immunotherapy product that has the capability of treating a number of different liquid tumors,” said Anthony Cataldo, Executive Chairman of GT BioPharma.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OXIS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.